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DOI: http://dx.doi.org/10.1016/j.hemonc.2013.05.001INTRODUCTION: Research has implied that the immune system plays a role in the pathogenesis of MDS and
that T-cells are reacting to tumour antigen present on the surface of the malignant cells. This could imply that the
immune system could be utilized to generate immune based therapy. The aim of this pilot study was to examine
the feasibility of studying this further by analysing the interaction of dendritic cells with T-cells in a small cohort
of MDS patients.
METHODS: Dendritic cells were generated in 6 MDS patients and 9 controls by culturing monocytes with GM-
CSF and IL-4. After activation with LPS and TNFa, the dendritic cells were analyzed for expression of co-stim-
ulatory and activation antigens. Thereafter, they were co-cultured with T-cells and the T-cell response was
examined by measuring the % change in expression of the activation antigen CD69.
RESULTS: MDS MoDC had reduced expression of HLA-DR (p=0.006), CD11c (p=0.0004), CD80 (p=0.03) and
CD86 (p=0.003), while resting T-cells from MDS patients had higher expression of the activation antigen CD69
on all subsets. The % change in CD69 expression increased significantly for both the control and MDS T-cells
after co-culture with allogeneic dendritic cells, however this change was lower in the MDS group. Despite the
increased CD69 expression prior to culture, MDS MoDC significantly up-regulated CD69 expression on autol-
ogous T-cells to values that were statistically higher than control cells.
CONCLUSION: This initial study suggests that the T-cells in MDS are able to respond to dendritic cells and are
therefore probably not part of the malignant clone. It further implies that the dendritic cell population could be
capable of presenting antigen and initiating an immune response and therefore further study is both feasible and
warranted.The myelodysplastic syndromes (MDS) are aheterogeneous group of clonal disorders char-acterised by peripheral blood cytopaenias,
ineffective hematopoiesis and dysplasia of one or more
bone marrow cell lines.1,2 It has been suggested that
the immune system is activated in MDS patients
and plays a role in the pathogenesis of the disease.
This theory has been supported by studies which haveHematol Oncol Stem Cell Ther 6(2) Second Quarter 2013demonstrated increased apoptosis in the bone mar-
row, oligoclonality of the T-cell population and in-
creased expression of activation antigens on the
surface of the T-cells.1–4 It has been hypothesised that
these activated T-cell clones are reacting to antigens
expressed on the surface of the malignant cells.5,6
Myeloid dendritic cells are effective antigen pre-
senting cells and central to the immune reaction. After49
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encountering the antigen they mature, migrate
through the tissues to secondary lymphoid organs where
the processed antigen is presented toT-cells in association
with Major Histocompatibility Complex MHC mole-
cules. The T-cells become activated, proliferate and initi-
ate an antigen speciﬁc immune response.7 However,
antigen presentation by dendritic cells can also induce an-
ergy which can result in the expansion of regulatory
T-cells (Tregs) and the possible down-regulation of the
immune response. This occurs if the dendritic cells do
not mature fully or fail to express co-stimulatory mole-
cules whichT-cells require to become activated.8,9Macro-
phages, monocytes and dendritic cells have been shown to
be part of the MDS clone10,11 and previous studies have
suggested that Monocyte derived Dendritic Cells MoDC
cells in MDS patients are reduced in number and have a
decreased ability to express activation antigens, secrete
cytokines and stimulate allogeneic T-cells.12–14 These
abnormalities could further lead to defective interaction
with autologous T-cells and may also alter
haematopoiesis.
Dendritic cells have been used in the treatment of
many solid and haematological malignancies and some
studies have been successful in generating immune
responses.8,15 Recently, leukaemia-derived dendritic cells
have been generated frompatients with acutemyeloid leu-
kaemia and have been able to initiate anti-leukaemia T-
cell responses in some cases.16,17 These studies suggest
that dendritic cells andT-cells could be utilised to develop
therapies that harness the patient’s own immune response
to treat haematological malignancy. Therefore, in order to
better understand the role of the immune system in mye-
lodysplasia and to ascertainwhether it would be feasible to
further investigate MDS dendritic cells and induce them
to present tumour antigen toT-cells, we performed a pilot
study on a small cohort of patients. The aimwas to exam-
ine the interaction of mature monocyte derived dendritic
cells with both allogeneic and, more importantly, autolo-
gous T-cells in patients with symptomatic MDS.METHODOLOGY
Patients and controls
The ability of dendritic cells to up-regulate co-stimu-
latory antigens and to activate autologous and alloge-
neic T-cells ex vivo was analysed in 6 patients and
compared to 9 normal controls. The study was ap-
proved by the University of Cape Town Ethics Com-
mittee and both patients and normal control groups
were required to read and sign a consent form prior
to any samples being taken. The diagnosis of myelo-dysplasia was made according to criteria proposed
by the World Health Organisation (WHO) classiﬁ-
cation of malignancies.18,19
Isolation of monocytes and generation of immature
monocyte derived dendritic cells
Monocytic cells are known to adhere to plastic. Therefore,
in order to isolate the monocytes and generate dendritic
cells the method of plastic adherence was utilised. 30 ml
of peripheral blood was collected aseptically into sterile
heparin vacutainer tubes and the mononuclear cells were
separated from the whole blood using Ficoll density cen-
trifugation (1.077 g/ml: Histopaque – Sigma–Aldrich).
Thereafter, the cells were washed using RPMI (RPMI-
1680, Sigma–Aldrich) and re-suspended in 24 ml RPMI
containing 20% AB serum (Western Province Blood
Transfusion Service; Cape Town, South Africa). 3 ml
of the cell suspension with a median cell concentration
of 1.33 · 106/ml (r = 0.9–2.8) in the controls and
0.9 · 106/ml (r = 0.5–3.4) in the MDS group, was
added to each of the eight culture plates in order for plastic
adherence to take place. After 2 h incubation at 37 C the
non-adherent cells were removed, centrifuged and recon-
stituted with 1 ml RPMI. The % of non-adherent cells
expressing the monocytic antigen CD14 and the T-cell
antigen CD3 was analysed for quality control purposes.
These cells were then discarded.
The generation of immature dendritic cells was
achieved by adding 3 ml of RPMI which contained 20%
AB serum, 10 ng/ml (1 · 104 units per 1 lg) GM-CSF
(G 5035, Sigma Aldrich) and 10 ng/ml IL-4 (1 · 104
units per 1 lg) (I 4269, Sigma Aldrich) to the remaining
adherent cells (monocytic cells) in each culture plate. The
cells were incubated for 5 days at 37 C in a humidiﬁed
CO2 incubator and thereafter removed and analysed for
the expression of dendritic cell antigens. The percentage
of dendritic cell yield was calculated by dividing the cell
count after culture with cytokines, with the cell number
originally put into culture. The panel of antibodies used
for analytical purposes consisted of HLA-DR (Becton
Dickinson), CD11c (Becton Dickinson), CD80 (Immu-
notech), CD86 (Becton Dickinson), CD83 (Immuno-
tech) and CD1a (Becton Dickinson). CD14
(Immunotech) and CD3 (Immunotech) were also in-
cluded in the panel to establish the number of monocytes
and T-cells present in the cell suspension. Analysis of the
MoDC was performed using a Becton Dickinson Fac-
sCalibur ﬂow cytometer utilising a standard four colour
protocol. Antigen presenting cells were identiﬁed as large
cells expressing high forward and side scatter and the
percentage positivity was compared to an isotypic neg-
ative control.Hematol Oncol Stem Cell Ther 6(2) Second Quarter 2013
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The ex vivo generated immature dendritic cells were
counted using a particle counter (Model: Zf, Coulter
Electronics – Hialeah, Florida, USA) and thereafter
re-plated with a median cell concentration of
0.1 · 106/ml (r = 0.05–0.24) in the MDS patients
and 0.16 · 106/ml (r = 0.08–0.26) in the control
group. In order to mature and activate the dendritic
cells, 10 ng/ml (1 · 105 units per 1 lg) TNFa, Sigma
Aldrich and 1 lg lipopolysaccharide (LPS) (5 · 105
units per mg) (L6529, Sigma Aldrich) were added
to the dendritic cell medium and incubated for a fur-
ther 72 h at 37 C in 5% CO2. An aliquot of the acti-
vated dendritic cells was then analysed for changes in
the expression of co-stimulatory and activation anti-
gens using the same gating strategy, ﬂow cytometer
settings and panel of antibodies were employed for
the analysis of the immature dendritic cells. The re-
sults were compared to a series of age matched normal
controls and to the antigenic expression of the cells
prior to activation and maturation.Addition of T-cells
The effects of the activated MoDC on T-cells was
analysed by co-culturing allogeneic or autologous lym-
phocytes with the mature dendritic cells. This was
achieved as follows: 30 ml of peripheral blood was
again venisected (7 days later) from each patient
(autologous) and from third party allogeneic normal
donors. After Ficoll separation, the cells were washed
and enumerated. The autologous or third party allo-
geneic lymphocytes were then plated with the acti-
vated dendritic cells at a ratio of 1 dendritic cell to
10 lymphocytes in dendritic cell medium containing
GM-CSF and IL-4. In order to determine the occur-
rence of an allogeneic response between residual
autologous T-cells and donor T-cells, four of the
plates containing MoDC (stimulator cells) were irra-
diated (30 Gy) prior to the addition of the donor
T-cells, while the other four were processed without
irradiation. The effects of the irradiation on the T-
cells and dendritic cells were then compared. Normal
control dendritic cells were also cultured in the same
manner with autologous (their own) and with alloge-
neic lymphocytes (from another third party normal
individual and the MDS patient). All the culture
plates were incubated at 37 C with 5% CO2 for 72 h.Harvest and analysis of T-cell response
After 72 h, both the non-adherent and adherent cells
were removed from the culture plates using a mixture
of phosphate buffered saline and EDTA. Two millili-Hematol Oncol Stem Cell Ther 6(2) Second Quarter 2013tres was added to the culture plates and after 15 min
at 37 C, when all the cells had detached they were re-
moved, enumerated and centrifuged. In order to mea-
sure the response of the T-cells to co-culture with the
dendritic cells, a method described by Maino et al.
was utilised.20,21 Brieﬂy, the percentage of CD3+,
CD4+ and CD8+ T-cells expressing the activation
antigen CD69 was measured by ﬂow cytometry both
pre and post culture with the mature dendritic cells.
The response rate or % change in CD69 expression
was calculated by multiplying the post CD69 values
by 100 and dividing this with the pre values (post
%CD69 · 100/pre %CD69). To study each T-cell
population, the gating strategy combined side scatter
and the expression of each speciﬁc T-cell antigen (Fig-
ure 1). The results from the MDS patients were com-
pared to the results obtained using a series of normal
individuals.
Statistical analysis
Descriptive statistics were employed to deﬁne the
MDS and control study cell populations. Nonpara-
metric statistics were used to compare results of the
proportion of cells expressing maturation markers as
well as ﬂuorescence intensity in normal individuals
and were compared to results from patients with
MDS. The probability (p = 0.05) was considered sig-
niﬁcant. Analysis was performed with the Statistical
software package (StaSoft).RESULTS
Patient population (Table 1)
Six patients with a diagnosis of myelodysplastic syn-
drome were studied and the results were compared
to nine normal individuals. The median ages of the
patient population and the control group were 63
(range: 49–70) and 44 (range: 22–55) years (Table 1)
respectively. None of the individuals with MDS had
received any biological treatment, however as Groote
Schuur Hospital is a referral centre, all the patients
were transfusion dependent. Monocyte dendritic cells
were generated from both patient and control samples
and then co-cultured with both allogeneic and autol-
ogous T-cells. The response of the T-cells was mea-
sured using multiparameter ﬂow cytometry.
The activation of antigen presenting cells and
dendritic cells (Figure 2A and B)
After the initial ﬁve day culture the MoDC yield was
calculated by dividing the number of immature den-
dritic cells with the original number of mononuclear
cells put into culture. The % yield in the MDS group51
Figure 1. Flow cytometric dot plots demonstrating the gating strategy used to isolate the T-cell population and analyse the percentage of cells
expressing CD69. Results are shown as median and range bars.
Table 1. Patient demographics.
Patient Sex Age Diagnosis IPSS score Cytogenetics % Blast in bm Leucocytes (· 109/l) Platelets (· 109/l Haemoglobin (g/dl)
1 F 56 RCMD 0 46XX <5 3.7 179 8.2
2 M 70 RAEB 1 46XY <5 0.89 155 12.9
3 M 49 RCMD 0.5 46XY- <5 5.15 56 7.7
4 F 68 RCMD 1 No metaphases 2.83 269 6.8
5 M 69 RAEB 0.5 <5 2.57 14 6.9
6 F 67 Hypoplastic MDS 0.5 46XX <5 1.41 15 7.9
52
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43) compared to 6.7% (r = 4.1–20.5) in the normal
samples. Flow cytometry was performed on the imma-
ture and on the mature dendritic cells after the activa-tion step. Prior to activation, the percentage of
immature MDS dendritic cells expressing the surface
antigens HLA-DR (p = 0.06) and CD11c (p = 0.05)
was reduced in comparison to the control group (Fig-Hematol Oncol Stem Cell Ther 6(2) Second Quarter 2013
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Figure 2. Bar graphs, demonstrating: (A) Immature dendritic cells: Compared to control cells, the % of MDS MoDc expressing dendritic cell
antigens HLA-DR (p = 0.06) and CD11c (p = 0.05) was reduced when compared to controls (B) Mature dendritic cells: After stimulation with LPS and
TNFa the % of MDS MoDc had reduced up regulation of HLA-DR (p = 0.006), CD11c (p = 0.004), CD80 (p = 0.03) and CD86 (p = 0.003) when
compared to normal controls.
STIMULATION OF AUTOLOGOUS T-CELLS IN PATIENTS original research reporture 2A). After activation, the dendritic cells from the
MDS patients had signiﬁcantly reduced expression of
HLA-DR (p = 0.006) and CD11c (p = 0.0004). In
addition, they failed to up-regulate the co-stimulatory
molecules CD80 (p = 0.03) and CD86 (p = 0.003)
which were signiﬁcantly reduced when compared to
normal controls (Figure 2B). However, the percentage
of cells expressing the dendritic cell speciﬁc antigen
CD83 was not signiﬁcantly different to the control
group (p = 0.4), implying that the number of den-
dritic cells was not decreased. Cells from the MDS
group showed a wide variation in antigen expression
as measured by the mean ﬂuorescent intensity
(MFI), which was reduced for HLA-DR, CD11c
(p = 0.01), CD83 (p = 0.06), CD80 (p = 0.03), and
CD86 (p = 0.003). These results indicate that after
exposure to LPS and TNFa as stimulation agents,
although the percentage yields and number of MoDC
are similar, fewer cells express activation markers sug-
gesting an abnormal development.
The response of T-cells after co-culture with
dendritic cells (Figure 3A–C)
Comparative studies of lymphocytes cultured with
irradiated and non-irradiated allogeneic dendritic cells
demonstrated that there was no signiﬁcant difference
in the CD69 expression on CD3+, CD4+ and CD8+
T-lymphocytes. Due to limited cell numbers, it was
therefore decided to discontinue further irradiation
of the culture plates.
Subsequently, the interaction of the mature acti-
vated dendritic cells with both autologous and alloge-
neic T-cells was investigated. After 72 h, the responseHematol Oncol Stem Cell Ther 6(2) Second Quarter 2013rate of the CD4, CD8 and CD3+ T-cell subsets was
analysed by comparing the expression of the activation
antigen CD69 both before and after incubation with
the dendritic cells (Figure 1). The percentage of rest-
ing MDS T-cells expressing CD69 was higher than
normal controls in the CD3+ (p = 0.009), CD4+
(p = 0.05) and CD8+ (p = 0.05) populations, sug-
gesting that T cells from MDS patients were already
activated (Figure 3A).
As expected, normal control T-cells co-cultured
with normal allogeneic MoDC led to signiﬁcantly in-
creased expression of CD69 on all T-cell subsets. In
contrast, normal T-cells cultured with dendritic cells
from MDS patients showed very little change in
CD69 expression compared to resting T-cells (Fig-
ure 3B). The median % change of CD69 expression
before and after co-culture was signiﬁcantly higher
in the control group (T-cells cultured with normal
dendritic cells) for CD3+ (1788 vs. 196; p = 0.007)
and CD8+ (1736 vs. 300; p = 0.006) T-cell subsets.
The next set of experiments examined the response
of T-cells after co-culture with their own monocyte
derived dendritic cells (autologous response). T-cells
from normal individuals co-cultured with their own
generated mature MoDC showed a modest but signif-
icant increment in CD69 expression on the CD3+
(p = 0.01), CD4+ (p = 0.07) and CD8+ (p = 0.04)
lymphocytes. In contrast, after co-culture with their
own MoDC, the percentage of MDS T-cells express-
ing CD69 also increased signiﬁcantly from baseline
values (p = 0.01, 0.03 and 0.04 respectively; Fig-
ure 3C) and appeared to signiﬁcantly exceed the re-
sponses by the normal T-cells (CD3 p = 0.01; CD453
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Figure 3. Bar graphs, demonstrating: (A) Resting T-cells: This graph compares the % of normal resting T-cells expressing CD69 with the resting T-
cells from MDS patients. Compared to control values, MDS T-cells had higher CD69 expression on CD3+ (p = 0.0009), CD4+ (p = 0.05) and CD8+
(0.05) subsets. (B) Allogeneic response: This graph compares the % of normal T-cells expressing CD69 after culture with normal allogeneic MoDC
with the % of normal allogeneic T-cells expressing CD69 after culture with MDS MoDC. Although the % change in CD69 expression increased in
both groups the T-cells co-cultured with MDS dendritic cells had a lower % expression in CD3+ (p = 0.05), and CD8+ (p = 0.02) T-cells. (C)
Autologous response: This graph compares the % of normal T-cells expressing CD69 after co-culture with their own MoDC with that of MDS T-cells
co-cultured with their own MDS derived dendritic cells. The % of MDS T-cells expressing CD69 was significantly increased in the CD3+ (p = 0.01)
and CD4+ (p = 0.01) populations. Legend: C stands for control samples. MDS stands for blood taken from patients with myelodysplastic syndrome.
The graphs demonstrate median and range bars.
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expression of CD69, the % change in expression was
similar for both groups in all T-cell populations stud-
ied (535% vs 552%; p = 0.08; 388% vs. 536%; p = 0.1
and 685% vs. 380%; p = 0.87).
In summary, resting T-cells fromMDS samples had a
higher expression of CD69 than control samples, imply-
ing that they were in an activated state and although both
MDS and control dendritic cells induced a signiﬁcant
change in CD69 expression on allogeneic normal T-cells,
the%CD69 expressionwas signiﬁcantly higher when cul-tured with normal dendritic cells. Signiﬁcantly, when
autologous MDS T-cells were co-cultured with their
own MDS MoDC, the % change in CD69 expression
was enhanced and equal to that obtained in the control
group, implying an adequate T-cell response.DISCUSSION
Dendritic cells have been utilised in the treatment of
many solid and haematological malignancies and
although further research is required, most studiesHematol Oncol Stem Cell Ther 6(2) Second Quarter 2013
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have been successful in generating immune
responses.8,15,22 Some of the poor clinical responses
recorded in diseases such as myeloma have been
attributed to dysfunctional dendritic cells which were
unable to stimulate T-cells.23 Therefore, in order for
immunotherapy to be successful, the ability of the
dendritic cells to activate T-cells needs to be assessed.
Recently, leukaemia-derived dendritic cells have been
generated from patients with acute myeloid leukaemia
and were able to initiate anti-leukaemia T-cell re-
sponses in some cases.16,17 Studies in our laboratory
and by other investigators have implied that the exces-
sive apoptosis and inhibition of colony growth de-
scribed in MDS patients is a consequence not solely
of the T-cells reacting with the CD34+ progenitor
cells, but of the complex interaction of the malignant
progeny with the bone marrow environment, includ-
ing stromal cells, dendritic cells and other cells of
the immune system.24–30 These ﬁndings suggest that
the T-cells, in MDS patients, could be responding to
processed tumour antigen and therefore may be uti-
lised in the development of immune based therapies.
In order to investigate the feasibility of studying this
concept further, we performed a pilot study on six
MDS patients in order to examine the role of T-cells
and their complex relationship with antigen present-
ing cells.
Dendritic cells are heterogeneous, consisting of
both myeloid and lymphoid subsets which follow dif-
ferent maturation pathways and produce subtypes
which have distinct morphology, antigen expression
and function.31 Myeloid dendritic cells are able to
stimulate an inﬂammatory T-cell response which is
capable of targeting tumour cells and because both
monocytes and dendritic cells have been shown to
be part of the MDS clone,10 the focus of our study
was on this subtype of the dendritic cell.
Previous studies have suggested that MoDC cells in
MDS patients are reduced in number and have a de-
creased ability to up-regulate activation antigens and se-
crete cytokines.13,14 As a defective response to TNFa
as well as poor ability to stimulate allogeneic T-cells
has been reported,12–14 our study was aimed, in addi-
tion, to investigate the interaction of MoDC with
autologous T-cells from MDS patients. Contrary to
previous studies,13,14 the median % yield of immature
MoDC in the MDS group was not signiﬁcantly differ-
ent from normal. This was further supported by the
percentage of cells expressing the dendritic cell speciﬁc
antigen CD83 which was similar to controls (p = 0.4).
In agreement with previous studies however,12–14 we
observed that after stimulation with LPS and TNFa
there was an inadequate up-regulation of co-stimula-Hematol Oncol Stem Cell Ther 6(2) Second Quarter 2013tory antigens (CD80 and CD86), HLA-DR and
CD11c in the MDS samples (Figure 2B). The de-
creased expression of CD80 (B7.1) and CD86 (B7.2)
is an important ﬁnding as these antigens bind to
CD28, CD40-ligand and other molecules expressed
on the surface of T-cells, which are essential for their
activation to take place.31 Decreased expression of
CD80 and CD86 suggests that the T-lymphocytes
may not be adequately stimulated, an observation asso-
ciated with anergy and the possible proliferation of T-
regulatory cells (Tregs) which could suppress the im-
mune response.8,9 A study of peripheral blood Tregs
in 52 MDS patients demonstrated an expansion of
CD4+ Tregs in late disease and lower numbers in
the earlier clinical subtypes.32 While we did not study
Tregs generation, and our sample group is small, we ob-
served that the activated MoDC in a patient with early
stage disease retained the capacity to increase the
expression of CD80 and CD86 and was able to stimu-
late the effective expression of CD69 on allogeneic T-
cells. This was in contrast to patients who were in more
advanced stages of MDS. This may be important as
activation of the immune system may vary with disease
progression.
In a further step, we examined the ability of alloge-
neic and autologous T-cells to up-regulate CD69
expression after co-culture with MoDC. We have also
shown that when compared to control samples, the
autologous CD3+, CD4+ and CD8+ T-cells have in-
creased expression of CD69 even before co-culture
with MoDC. In support of previous reports,12,14
our results demonstrated that in MDS, ex vivo gener-
ated dendritic cells have the capacity to stimulate nor-
mal allogeneic T-cells, however this was signiﬁcantly
reduced when compared to normal MoDCs
(Figure 3B).
In addition, our study has revealed a novel and inter-
esting observation in that the expression of CD69 on
autologous MDS T-cells after co-culture with MoDC
(Figure 3C) exceeded the allogeneic reaction. This en-
hanced expression of CD69 on autologous CD3+,
CD4+ and CD8+ subsets led to an increased % change
in the expression of CD69 that was equal to the normal
T-cells co-cultured with their own MoDC. This could
imply an anti-tumour T-cell response to the haemopoi-
etic precursors which has been previously pro-
posed.5,6,33 Therefore, although MoDC, derived from
MDS patients may not have a similar phenotype to
normal, they appear to be able to interact with autolo-
gous T-cells and could inﬂuence the immune response.
It also implies that MDS T-cells are able to respond to
dendritic cell stimulation and are probably not part of
the malignant clone.55
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Multiple blood transfusions have been shown to
stimulate immune cells with the consequent activation
of T-cells.34 This could be important as our hospital
is a referral centre and these MDS patients were al-
ready transfusion dependent upon entering the study.
This could have contributed to the activated immune
environment observed and could also have an inﬂuence
on all studies which examine immune responses in
MDS patients. Nevertheless, even though the expression
of CD69 on MDS T-cells was increased pre-culture, in
our cohort of patients, this expression increased even
more post-culture with MoDC (Figure 3C).
The % change of CD69 expression on CD4+ T-
cells could be relevant as this subset of cells consists
of numerous sub-populations, all of which inﬂuence
the immune response in different ways. These include
both suppression by T regulatory cells (regs) and/or
the induction of an inﬂammatory response (Th1).35
Tregs cells include CD4+CD25+Foxp3+Tregs
which are either naturally occurring or stimulated
by tolerogenic dendritic cells, Tr1 cells which express
the immunosuppressive cytokine IL-10 and Th3
Tregs which express TGF-a and lack CD25.36,37 A
fourth subtype of the Treg cell has also been identi-
ﬁed. This sub-group is CD4+, CD25, Foxp3,
CD122+ and interestingly CD69+. They have high
levels of TGF-1b which inhibits T-cell proliferation
and experiments in cancer bearing mice have shown
that as their tumours progress the numbers of
CD4+CD69+CD25-Tregs increase, suggesting that
this sub-type of Tregs could play an important role
in the progression of malignancies.38 Our results have
demonstrated an increase in CD4+CD69+ T-cells
after co-culture with dendritic cells which could imply
that the MDS dendritic cells may be stimulating a
population of Treg cells which have the ability to in-
hibit an anti-tumour response. On the other hand, it
has also been shown that there is an increase of Th1
cells in MDS and that IL-17 producing CD4+ cells
are increased in the early stages of the disease.39,40
CD4+ T-helper cells are also important in the main-
tenance of cytotoxic CD8+ T-cell activation41 and
therefore could play a vital role in stimulating and
maintaining an inﬂammatory response. Our initial re-
sults therefore indicate that future studies should fo-
cus on the inﬂuence of dendritic cells on all the sub-
types of CD4+ T-cells. This should include the anal-
ysis of CD69+ Tregs and the expression of TGF-b.
We have also shown that the CD8+T-cells had sig-
niﬁcantly increased CD69 expression prior and after
co-culture (Figure 3A). In a study of trisomy 8+
MDS patients, all had signiﬁcantly expanded oligoclo-
nal CD8+ T-cells which inhibited clonogenic cellgrowth when in direct cell contact with haemopoietic
progenitors.42 These ﬁndings implied that the CD8+
T-cells were responding to the presentation of antigens
in association with MHC-Class I molecules and while
the mechanism of this response was not clear this could
be important in the generation of immune based ther-
apies. The ability of theMDS dendritic cells to interact
with target T cells should therefore be further studied
by stimulating them with speciﬁc antigens and thereaf-
ter measuring speciﬁc T-cell responses using MHC-
tetramers or other methods. In patients responsive to
immunosuppressive therapy, signiﬁcant T-cell stimula-
tion was demonstrated against theWilms tumour anti-
gen (WT1) suggesting that the WT1 protein could be
one of the antigens which initiate an immune response
inMDS.43 TheWT1 antigen could however also stim-
ulate the production of WT1 speciﬁc Treg cells which
recognise theWT1 antigen. Experiments by Lehe et al.
generated anti WTI speciﬁc T-cell lines which dis-
played a Th2 phenotype, recognised HLA-matched
WT1+ leukemic cells and inhibited the activity of allo-
geneic T-cells without any direct cell contact. These
WT1 speciﬁc Treg cells were able to induce apoptosis
of the dendritic cells but although they inhibited the
proliferation of CD8+ cytotoxic T-cells, they did not
have an effect on their cytotoxic function.44 These re-
sults are important as the generation of antigen speciﬁc
T-cells in MDS and other malignancies may be limited
by the proliferation of antigen speciﬁc Tregs whichmay
require depletion in order for success to be achieved.
The results of this initial study suggest that the
mechanism of dendritic cell interaction with T-cells
is preserved and that T-cells are probably normal
and not part of the malignant clone. Therefore, the
abnormal activated environment that is responsible
for many of the features observed in patients with
MDS is probably the result of the complex interaction
of all the cells in the bone marrow including the stem
cells themselves, the bone marrow stroma and the
abnormal cytokine milieu. The ability of the T-cells
to respond to the MoDC could also suggest that
the immune system may be utilised in the develop-
ment of immune based therapies. However, as previ-
ously described, dendritic cells in malignant
environments have the ability to not only stimulate
an inﬂammatory response but also the proliferation
of Tregs. Although CD69 has been well described
as an early activation molecule,20 recent evidence sug-
gests that this antigen could also be expressed by
Tregs and plays a role in inhibiting T-cell prolifera-
tion.44 Therefore, although we have demonstrated
that MDS dendritic cells are able to stimulate
CD69 expression on T-cells, further analysis of theseHematol Oncol Stem Cell Ther 6(2) Second Quarter 2013
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CD69+ T-cell populations and their relationship
with the dendritic cells in MDS is required before
successful immune based therapies can be achieved.Hematol Oncol Stem Cell Ther 6(2) Second Quarter 2013Acknowledgement
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